ED Pde 5i denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for ed pde5i are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Your PDE5 Inhibitor as Duplicate Therapy

A duplicate-therapy denial means Cigna's system flagged that you appear to already have an active claim or recent fill for another medication in the same therapeutic class — in this case, the phosphodiesterase type-5 (PDE5) inhibitor class used to treat erectile dysfunction (ED). This is one of the more technically fixable denial categories because it is frequently triggered by an administrative mismatch rather than a genuine clinical disagreement.

## Why This Denial Is Appealable

Duplicate-therapy logic is applied algorithmically by pharmacy benefit systems. Common causes include a prior fill that was returned or never picked up, a coverage transition between plans that left a claim artifact, or a prescriber trial of a different agent that has since been discontinued. None of these scenarios represents actual concurrent duplicate use. If your prescriber has documented a clinical reason to use the requested agent specifically — distinct mechanism-of-action nuances, tolerability, or co-morbid conditions that favor one agent over another within the class — that clinical rationale directly rebuts the duplicate finding.

## Federal Appeal Framework

You have enforceable rights under two parallel frameworks. If your plan is governed by the Affordable Care Act (ACA), Section 2719 guarantees access to an independent external review by an accredited Independent Review Organization (IRO) after you exhaust internal appeals. If your coverage is employer-sponsored and governed by ERISA, Section 503 requires a full-and-fair review with written reasoning. In most ACA-compliant plans the window to file an external review request is approximately 4 months from the date of the final internal denial. An expedited (72-hour) review is available when your prescriber certifies that waiting the standard timeframe would seriously jeopardize your health.

## Concrete Appeal Steps and Timeline

1. Request the denial rationale in writing — obtain the Explanation of Benefits (EOB) and the specific duplicate-therapy rule Cigna applied. 2. Obtain a pharmacy claims printout — ask your pharmacy or Cigna's member portal for a 12-month medication history that shows no overlapping active fill. 3. File the internal appeal — Cigna's standard internal review period is typically 30 days for non-urgent pharmacy appeals; confirm the exact deadline on your EOB. 4. Escalate to external review if denied — if Cigna upholds the denial internally, request IRO review before the 4-month window closes.

## Documentation to Gather

• Diagnosis confirmation: Chart notes establishing an ED diagnosis and any underlying contributing conditions.
• Medication history: Pharmacy records showing prior agents tried, dates, and that no duplicate is currently active.
• Prescriber letter: A medical-necessity letter from your physician explaining why the requested PDE5 inhibitor is the appropriate agent and that there is no concurrent duplicate therapy.
• Criteria-mapping table: List each condition in Cigna's published coverage policy for this drug class, then answer each with the specific chart fact that satisfies it. Obtain Cigna's current medical/pharmacy policy document directly from their provider or member portal before building this table.